MedTech Announces 2010-2011 Board Elections
Friday, November 19, 2010
SYRACUSE, NY—MedTech, the hub of Upstate New York’s bioscience and medical technology industry, is excited to announce its 2010-2011 Board of Directors election results.
Two Albany-area executives have been named to the board:
Bela Musits, managing director at High Peaks Venture Partners was re-elected to the board as a Director-at-Large. Musits is a founding managing director of High Peaks Venture Partners, L.P. High Peaks is an early-stage technology venture fund that focuses on making investments across New York State. Prior to High Peaks, Musits was the director of Rensselaer Polytechnic Institute's Incubator Program. He is the founder of two venture-backed companies and has held senior management and technical positions at the corporate research labs of IBM and GE. Musits also managed the successful spin-off of technology from IBM Research, serving as co-founder and president of a computer-guided robotic surgery company. He raised more than $17 million in capital and positioned the company for a successful IPO in 1997.
Rob Rossell, senior vice president and disease state leader for AngioDynamics Inc., was elected. Rossell has global responsibility for the Oncology Access Disease State and was part of the management team that founded the company 20 years ago. He has held several senior positions over that time including senior vice president/general manager of the Access Division, vice president of corporate accounts, and vice president of marketing. Prior to those roles, he held positions as the director of marketing and product manager. Prior to helping start AngioDynamics, Rob worked for North American Instrument Corporations (NAMIC), in Glens Falls.
Four Syracuse-area executives have been named to the board:
Mitch Katz, partner at Menter Rudin & Trivelpiece, was re-elected as a director-at-large and secretary of the board, and also serves on the Finance Committee. Katz handles commercial litigation in state and federal courts in cases involving creditors' rights, lender liability defense, limited liability companies and partnerships, shareholder disputes in closely held corporations, contract disputes, trade secrets and technology licensing matters, employers' rights under non-competition and confidentiality agreements, and contested commercial foreclosure actions. He also provides litigation support to the firm’s Business Restructuring and Bankruptcy practice group in complex matters arising under and in connection with cases filed under Chapter 11 of the bankruptcy code.
George Langford, Ph.D., dean of the College of Arts and Sciences at Syracuse University was elected to the board. Langford is a nationally-known cell biologist and neuroscientist. Since coming to SU in 2008, he has helped build Arts and Sciences into one of the nation’s premier residential liberal arts colleges. He also has been instrumental in creating external partnerships with the National Academy of Science and Brookhaven National Laboratory. Langford was named inaugural chair of the Minority Affairs Committee of the American Society for Cell Biology, and was appointed to the National Science Board to advise President Clinton and Congress on national science policy. He is the recipient of more than two-dozen awards and honors, including the 2009 Professional Achievement Award from the Illinois Institute of Technology, where he earned a M.S. and Ph.D. in cell biology.
Doug Linquest, executive vice president of strategy & business development for Welch Allyn was elected to the board. Linquest oversees Welch Allyn's Beaverton, OR facility and serves the company with overall site management of this location. In addition to managing the day-to-day operations in Beaverton, he is responsible for strategy and business development, corporate communication and Welch Allyn's defibrillation business unit. A native of Skaneateles, NY, Linquest started his career at Welch Allyn in 1983 and has worked in a variety of sales, marketing, and executive leadership roles. He holds a B.A. in English from Colgate University and an M.B.A. from Syracuse University. He is a member of the Executive Board of Directors of the Oregon Bioscience Association.
Dave Nocilly, partner at Bond Schoeneck & King, has been re-elected as a director-at-large, and chairs the Issues, Events and Services Committee. Nocilly is a registered patent attorney who has prepared and prosecuted numerous patent applications for electromechanical, biomedical, and mechanical inventions. He also handles the enforcement of the full range of IP rights, including the litigation of patent, trademark, and copyright matters. Nocilly is an adjunct professor at Syracuse University College of Law. He received his J.D. summa cum laude from Syracuse University College of Law.
Four Rochester-area executives have been named to the board:
Don Boyd, Ph.D., vice president for research at Rochester Institute of Technology was re-elected to the board.As vice president for research at the Rochester Institute of Technology, Boyd works with the RIT faculty, staff and students to identify research programs, funding sources through government, state and corporate collaborations, and technology transfer opportunities through intellectual property management, new company startups and outreach programs. Boyd received his PhD in Computer Science from the University of Iowa in 1971.
Martin Brusdeilins, Ph.D., vice president, R&D Worldwide for Ortho Clinical Diagnostics was re-elected to the board. In his role at OCD, Brusdeilins oversees new product development, research, and product support in Rochester, NY. His work encompasses the fields of clinical diagnostics, immunodiagnostics, immunohematology and blood screening equipment, and he serves as a member on the OCD Global management board. Prior to joining OCD in 2003, Brusdeilins spent 17 years at Roche Diagnostics. Most recently he was senior vice president and head of R&D for Roche Near Patient Testing in Graz, Austria. Brusdeilins earned his B.S. and Ph.D. in biochemistry from Eberhard Karls University, Tuebingen, Germany.
Lorraine Ellis, president & CEO of Research Dynamics Consulting Groupwas re-elected to the board. Ellis has more than 30 years experience in the pharmaceutical industry working at several pharmaceutical companies in positions ranging from associate pharmacologist to director of medical project planning and development. Ellis holds a B.A. in biology from Hofstra University, M.S. in biology from Adelphi University, and MBA from Rochester Institute of Technology. Continuing her work in education, she is an Adjunct Professor at RIT and on the RIT Clinical Advisory Board to develop a new Master’s degree in Clinical Research Management and an Adjunct Assistant Professor for MGH IHP Graduate Program in Clinical Investigation.
Bob Ruppenthal, president of RTEmd was elected to the board and named chair of the Marketing and Membership Development Committee. For nearly thirty years, Ruppenthal has led RTEmd in strategic direction, business development and administration. His company is focused on development and testing of software for regulated medical devices in clinical diagnostics, medical imaging and information systems. Before founding RTEmd, Ruppenthal was a practicing electrical engineer designing hardware and software for complex systems in aerospace and medical applications.
Two Buffalo-area executives have been named to the board:
Paul Buckley,president of Applied Sciences Group was elected to the board. Buckley has been president of Applied Sciences Group since 1997, serving in engineering, operations management and strategic development areas. He has a bachelor's degree in biomedical engineering and a master’s degree in systems engineering from RPI. Prior to his employment at ASG, Buckley worked in the aerospace and telecommunications industries in various engineering and management capacities. He currently chairs the University at Buffalo's Center for Entrepreneurial Leadership (CEL) Alumni Association and is the 2004 CEL Taylor Kew award recipient for entrepreneurial excellence. Buckley is a board member of the Buffalo Niagara Partnership, the UB School of Medicine's Dean's Council, and the Buffalo branch of the American Diabetes Association.
Ben Harp, chief operating officer of Polymer Conversions Inc., has been re-elected to the board. Harp joined Polymer Conversions Inc. in December 2003 as the director of business development. In June 2004 he became the chief operating officer. He holds a Master of Business Administration and a Bachelor of Science in Mathematics from Canisius College. He currently is the vice chair of the Life Science Council of the Buffalo Niagara Partnership and is on the board of directors for Manufacturers Association of Plastics Processors. Harp previously served on the board of directors for the Society of Plastics Industry from 2004 to 2007.
MedTech is an active association of pharmaceutical, biotech, and medical technology companies, their suppliers and service providers, and research universities. We boost the growth and prosperity of our members by connecting them for collaboration, offering educational programs, sharing news and information, and advocating for the industry with government and leaders. Our mission is to develop the relationships, tools and programs that enable Upstate New York companies to bring tomorrow’s medical solutions to the healthcare marketplace. For more information, visithttp://www.medtech.org
View All News »